FDA Removes 2003 Boxed Warning From Menopausal Hormone Therapy Products
Updated
Updated · Medscape · Jun 12
FDA Removes 2003 Boxed Warning From Menopausal Hormone Therapy Products
3 articles · Updated · Medscape · Jun 12
Summary
November 2025 marked a regulatory shift as the FDA dropped the boxed warning on menopausal hormone therapy products after more than 20 years of broad caution.
The change reflects a more individualized risk-benefit approach, replacing the old “lowest dose for shortest duration” framing with guidance that timing, formulation and patient profile matter.
Systemic estrogen can improve skin thickness, hydration and wound healing, while low-dose vaginal estrogen remains a targeted treatment for genitourinary syndrome of menopause, which affects 45% to 77% of postmenopausal women.
Risk differences still shape prescribing: transdermal estrogen has a more favorable venous thromboembolism profile than oral therapy, and low-dose vaginal products such as 4 μg estradiol show minimal systemic absorption.
Clinicians are still urged to use shared decision-making because hormone therapy is not approved for cosmetic skin rejuvenation and remains contraindicated in patients with bleeding, estrogen-dependent cancers, thromboembolic disease or liver disease.
Now that the FDA's major warning is gone, is hormone therapy the new fountain of youth for aging skin?
The FDA reversed its stance on hormone therapy. What long-term health risks are doctors still debating behind closed doors?
With hormone therapy's comeback, what hidden barriers still prevent millions of women from accessing its benefits?
FDA Removes Black Box Warning from Menopausal Hormone Therapy: A Landmark Shift in Women's Health Policy (2025)
Overview
On November 10, 2025, the FDA removed broad 'black box' warnings from most menopausal hormone therapy (MHT) products, marking a major shift in how these treatments are viewed and prescribed. This decision followed a comprehensive review of scientific evidence, including studies showing that MHT can reduce risks of fractures, heart disease, and cognitive decline. The removal of the warning is expected to have immediate and far-reaching effects, making it easier for women to access MHT and encouraging healthcare providers to reconsider its benefits and risks. This change aims to support more informed, individualized care for women experiencing menopause.